Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Lead Phase 3 Trial of Mocravimod for Acute Myeloid Leukemia
Priothera has appointed Dr. Jens Hasskarl as Chief Medical Officer to oversee the global Phase 3 MO-TRANS study of mocravimod in acute myeloid leukemia patients.
Evotec and Bristol Myers Squibb Achieve Major Milestone in Molecular Glue Degrader Collaboration, Triggering $75M Payment
Evotec SE announced significant progress in its strategic protein degradation collaboration with Bristol Myers Squibb, triggering performance-based payments totaling $75 million.
B-Cell Lymphoma Pipeline Expands with 300+ Therapies in Development for 2025
DelveInsight's latest report reveals a robust B-cell lymphoma pipeline with over 295 companies developing 300+ therapies, highlighting significant industry investment in this area.
AstraZeneca Acquires European Cell Therapy Biotech in Deal Worth Up to $1 Billion
AstraZeneca has expanded its cell therapy portfolio by acquiring a European biotech company in a deal valued at up to $1 billion, strengthening its position in the advanced therapeutics market.
Bayer and CRISPR Therapeutics Form $300 Million Joint Venture to Advance Gene-Editing Therapies
Bayer is investing $300 million over five years in a new joint venture with CRISPR Therapeutics, plus $35 million for a minority stake in the gene-editing pioneer.
Novel Chemo-Immunotherapy Approach Shows Promise for Advanced HPV-Negative Head and Neck Cancer
A Phase 2 clinical trial at UChicago Medicine demonstrated that combining nivolumab immunotherapy with chemotherapy led to tumor shrinkage in 53% of advanced HPV-negative head and neck cancer patients.
Decentralized Clinical Trials Show Promise in Boosting Diversity, Study Finds
Decentralized clinical trials (DCTs) are associated with increased representation of Asian, American Indian/Alaska Native, and female participants.
Global Biotechnology Market Projected to Reach USD 3.54 Trillion by 2033, Driven by Therapeutic Innovations
The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.
T-Cell Lymphoma Pipeline Shows Promise with Novel Therapies and Regulatory Support
The T-Cell Lymphoma drug pipeline is advancing with key players like Eisai, Takeda, and Rhizen Pharmaceuticals developing innovative therapies.
MRD Negativity Emerges as Key Endpoint in Multiple Myeloma Trials
Minimal Residual Disease (MRD) testing offers a sensitive method for detecting remaining cancer cells, influencing treatment decisions and improving patient outcomes in multiple myeloma.